Market capitalization | $45.17m |
Enterprise Value | $15.69m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.57 |
P/S ratio (TTM) P/S ratio | 4.52 |
P/B ratio (TTM) P/B ratio | 7.97 |
Revenue growth (TTM) Revenue growth | -20.00% |
Revenue (TTM) Revenue | $10.00m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Surrozen Inc forecast:
2 Analysts have issued a Surrozen Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 10 10 |
20%
20%
|
|
Gross Profit | 8.43 8.43 |
13%
13%
|
|
EBITDA | -25 -25 |
23%
23%
|
EBIT (Operating Income) EBIT | -27 -27 |
25%
25%
|
Net Profit | -44 -44 |
27%
27%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Surrozen, Inc. is a preclinical stage biotechnology company, which engages in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. It is also focused on developing tissue-specific antibodies designed to engage the body's existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. The company was founded on August 12, 2015 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Craig Parker |
Employees | 42 |
Founded | 2015 |
Website | www.surrozen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.